The GNB3 C825T polymorphism affects response to HCV therapy with pegylated interferon in HCV/HIV co-infected but not in HCV mono-infected patients.

Golo Ahlenstiel; Hans Dieter Nischalke; Karin Bueren; Thomas Berg; Martin Vogel; Michael Biermer; Frank Grünhage; Tilman Sauerbruch; Jürgen Rockstroh; Ulrich Spengler; Jacob Nattermann

The GNB3 C825T polymorphism affects response to HCV therapy with pegylated interferon in HCV/HIV co-infected but not in HCV mono-infected patients.

Standard

The GNB3 C825T polymorphism affects response to HCV therapy with pegylated interferon in HCV/HIV co-infected but not in HCV mono-infected patients. / Ahlenstiel, Golo; Nischalke, Hans Dieter; Bueren, Karin; Berg, Thomas; Vogel, Martin; Biermer, Michael; Grünhage, Frank; Sauerbruch, Tilman; Rockstroh, Jürgen; Spengler, Ulrich; Nattermann, Jacob.

in: J HEPATOL, Jahrgang 47, Nr. 3, 3, 2007, S. 348-355.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Ahlenstiel, G, Nischalke, HD, Bueren, K, Berg, T, Vogel, M, Biermer, M, Grünhage, F, Sauerbruch, T, Rockstroh, J, Spengler, U & Nattermann, J 2007, 'The GNB3 C825T polymorphism affects response to HCV therapy with pegylated interferon in HCV/HIV co-infected but not in HCV mono-infected patients.', J HEPATOL, Jg. 47, Nr. 3, 3, S. 348-355. <http://www.ncbi.nlm.nih.gov/pubmed/17559964?dopt=Citation>

APA

Ahlenstiel, G., Nischalke, H. D., Bueren, K., Berg, T., Vogel, M., Biermer, M., Grünhage, F., Sauerbruch, T., Rockstroh, J., Spengler, U., & Nattermann, J. (2007). The GNB3 C825T polymorphism affects response to HCV therapy with pegylated interferon in HCV/HIV co-infected but not in HCV mono-infected patients. J HEPATOL, 47(3), 348-355. [3]. http://www.ncbi.nlm.nih.gov/pubmed/17559964?dopt=Citation

Vancouver

Ahlenstiel G, Nischalke HD, Bueren K, Berg T, Vogel M, Biermer M et al. The GNB3 C825T polymorphism affects response to HCV therapy with pegylated interferon in HCV/HIV co-infected but not in HCV mono-infected patients. J HEPATOL. 2007;47(3):348-355. 3.

Bibtex

@article{9a4e7d00601d45f5926f9340dccd52b4,

title = "The GNB3 C825T polymorphism affects response to HCV therapy with pegylated interferon in HCV/HIV co-infected but not in HCV mono-infected patients.",

abstract = "BACKGROUND/AIMS: Response to HCV treatment with pegylated interferon-alpha is variable but might at least in part depend on genetic host factors. The G protein beta3 unit (GNB3) C825T polymorphism has been shown to affect treatment response in HCV mono-infection. Here, we analyzed the impact of the GNB3 genotype in the context of HCV/HIV co-infection. METHODS: HIV/HCV co-infected (n=112) and HCV mono-infected patients (n=150), receiving therapy with pegylated IFN-alpha/ribavirin, were enrolled into this study. Furthermore, we analyzed 220 healthy and 92 HIV mono-infected patients. GNB3 genotype was defined and correlated with respect to treatment response. RESULTS: GNB3 genotype distribution differed significantly between HIV/HCV co-infected patients and HIV-positive/HCV-negative (p=0.0002) or healthy controls (p=0.03). Patients with a GNB3 CC genotype had significantly lower SVR rates as compared to carriers of a non-CC genotype (52% versus 77%; p=0.018). In a logistic regression analysis the GNB3 genotype and the HCV genotype were significantly associated with response to treatment (p=0.018). In contrast to HIV/HCV co-infected patients, GNB3 genotype did not affect response to treatment in HCV mono-infected patients. CONCLUSIONS: The GNB3 825 CC genotype is associated with poor SVR rates in HIV/HCV co-infected patients. This underlines the impact of genetic host factors for treatment response.",

author = "Golo Ahlenstiel and Nischalke, {Hans Dieter} and Karin Bueren and Thomas Berg and Martin Vogel and Michael Biermer and Frank Gr{\"u}nhage and Tilman Sauerbruch and J{\"u}rgen Rockstroh and Ulrich Spengler and Jacob Nattermann",

year = "2007",

language = "Deutsch",

volume = "47",

pages = "348--355",

journal = "J HEPATOL",

issn = "0168-8278",

publisher = "Elsevier",

number = "3",

}

RIS

TY - JOUR

T1 - The GNB3 C825T polymorphism affects response to HCV therapy with pegylated interferon in HCV/HIV co-infected but not in HCV mono-infected patients.

AU - Ahlenstiel, Golo

AU - Nischalke, Hans Dieter

AU - Bueren, Karin

AU - Berg, Thomas

AU - Vogel, Martin

AU - Biermer, Michael

AU - Grünhage, Frank

AU - Sauerbruch, Tilman

AU - Rockstroh, Jürgen

AU - Spengler, Ulrich

AU - Nattermann, Jacob

PY - 2007

Y1 - 2007

N2 - BACKGROUND/AIMS: Response to HCV treatment with pegylated interferon-alpha is variable but might at least in part depend on genetic host factors. The G protein beta3 unit (GNB3) C825T polymorphism has been shown to affect treatment response in HCV mono-infection. Here, we analyzed the impact of the GNB3 genotype in the context of HCV/HIV co-infection. METHODS: HIV/HCV co-infected (n=112) and HCV mono-infected patients (n=150), receiving therapy with pegylated IFN-alpha/ribavirin, were enrolled into this study. Furthermore, we analyzed 220 healthy and 92 HIV mono-infected patients. GNB3 genotype was defined and correlated with respect to treatment response. RESULTS: GNB3 genotype distribution differed significantly between HIV/HCV co-infected patients and HIV-positive/HCV-negative (p=0.0002) or healthy controls (p=0.03). Patients with a GNB3 CC genotype had significantly lower SVR rates as compared to carriers of a non-CC genotype (52% versus 77%; p=0.018). In a logistic regression analysis the GNB3 genotype and the HCV genotype were significantly associated with response to treatment (p=0.018). In contrast to HIV/HCV co-infected patients, GNB3 genotype did not affect response to treatment in HCV mono-infected patients. CONCLUSIONS: The GNB3 825 CC genotype is associated with poor SVR rates in HIV/HCV co-infected patients. This underlines the impact of genetic host factors for treatment response.

AB - BACKGROUND/AIMS: Response to HCV treatment with pegylated interferon-alpha is variable but might at least in part depend on genetic host factors. The G protein beta3 unit (GNB3) C825T polymorphism has been shown to affect treatment response in HCV mono-infection. Here, we analyzed the impact of the GNB3 genotype in the context of HCV/HIV co-infection. METHODS: HIV/HCV co-infected (n=112) and HCV mono-infected patients (n=150), receiving therapy with pegylated IFN-alpha/ribavirin, were enrolled into this study. Furthermore, we analyzed 220 healthy and 92 HIV mono-infected patients. GNB3 genotype was defined and correlated with respect to treatment response. RESULTS: GNB3 genotype distribution differed significantly between HIV/HCV co-infected patients and HIV-positive/HCV-negative (p=0.0002) or healthy controls (p=0.03). Patients with a GNB3 CC genotype had significantly lower SVR rates as compared to carriers of a non-CC genotype (52% versus 77%; p=0.018). In a logistic regression analysis the GNB3 genotype and the HCV genotype were significantly associated with response to treatment (p=0.018). In contrast to HIV/HCV co-infected patients, GNB3 genotype did not affect response to treatment in HCV mono-infected patients. CONCLUSIONS: The GNB3 825 CC genotype is associated with poor SVR rates in HIV/HCV co-infected patients. This underlines the impact of genetic host factors for treatment response.

M3 - SCORING: Zeitschriftenaufsatz

VL - 47

SP - 348

EP - 355

JO - J HEPATOL

JF - J HEPATOL

SN - 0168-8278

IS - 3

M1 - 3

ER -